ALK and neoplasm: Regarding tumors without an activating ALK mutation, we postulate that unconjugated CDX0239 does not have a significant inhibitory effect on ALK signaling as we would expect to observe anti-tumor activity in the ALK-amplified NB-1 cell line and xenograft model as previously demonstrated with small molecular inhibition of ALK25.